Multiple myeloma is a blood cancer. It's the second most common blood cancer, but it's still a pretty rare cancer. It's one to 2% of all cancers, which comes down to about 35 thousand new cases per year. Lot of what we know about myeloma and where it originates that entire thought process was initiated out here at the Mayo Clinic. Mayo Clinic has the largest multiple myeloma group anywhere in the world. Our group has developed what is called the M smart risk stratification and recommendations for myeloma therapy. The primary goal is to tell patients what is the current best treatment for my along, whether it be newly diagnosed for relapsed or maintenance. We do a lot of cytogenetic testing on the bone marrow samples to find out precisely what type of myeloma patients have and what treatments they would respond to? Well, everyone should get a second consultation and reviewed at a tertiary center when you have a disease like multiple myeloma. So then you're really making that fast decisions on the most novel therapies. Male has been at the forefront of clinical trial development and have really helped answer key questions about the optimal treatment approach of this disease. I think truly this is a watershed moment in the management of the disease. Immunotherapies that have affected other cancers, also coming into myeloma and revolutionizing the way we think about the disease and we treat the disease. I always tell my patients there's a big army behind the scenes working for them. I have some of the world's best heart doctors, lung doctors, kidney doctors, surgeons ready to back me up in providing the best care for that patient. He matter pathologists, technicians and other researchers who in real time are working on either blood samples of clinical bone marrow samples to provide that information that I need to help provide patients with options to make the best decision on treatment. Because physician treating a patient with multiple myeloma, you're not just treating that patient. You're also helping their family or their loved one's understand more about the disease to help them take care of that patient. Watching our colleagues work together for one patient. And it's a really multidisciplinary practice and leveraging the knowledge of decades and that history, as well as all of the novel therapeutics to support our patients and continue to drive the science is going to make a difference.